Amorfix Life Sciences has entered into a collaboration with CNJ Holdings, a subsidiary of Cangene Corp., for the identification and development of therapeutic antibodies against disease specific epitopes (DSEs) for oncology indications, using Amorfix’s ProMIS discovery technology. The terms were not disclosed.    “This collaboration represents the ideal situation where two companies come together with complementary expertise, resources and technology in a united effort to identify an...